Investor Relations

News Releases

Webcast
Apadaz Update Call
Friday, February 23, 2018 at 2:30 PM EST
Date Title
06/26/17
Summary ToggleKemPharm Announces First Patent Grant for KP746, a Prodrug of Oxymorphone US Patent and Trademark Office issues patent protection to KP746, an investigational therapy for the treatment of pain with a prodrug of oxymorphone CORALVILLE, Iowa , June 26, 2017 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a clinical-stage specialty pharmaceutical company focused on the
06/09/17
Summary ToggleKemPharm to Present Clinical Data for KP511, an Opioid Prodrug Candidate, at the International Conference on Opioids Poster Presentation Highlights Intranasal Abuse Deterrence Technology CORALVILLE, Iowa , June 09, 2017 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a clinical-stage specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, will present clinical data
06/01/17
Summary ToggleKemPharm Announces Addition to Leadership Team Andrew Barrett , Ph.D., appointed Vice President, Scientific Affairs CORALVILLE, Iowa , June 01, 2017 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a clinical-stage specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, today announced an addition to
05/10/17
Summary ToggleKemPharm, Inc. Reports First Quarter 2017 Results Conference Call and Live Audio Webcast with Slide Presentation Scheduled for Today at 4:30 p.m. ET Clinical Development & Regulatory Highlights : Reported Positive Data from Proof-of-Concept Phase 1 Intranasal Pharmacokinetic Study of KP511 Announced Additional U.S.
05/01/17
Summary ToggleKemPharm, Inc. to Report First Quarter 2017 Results Conference Call and Live Audio Webcast with Slide Presentation Scheduled for May 10, 2017 , 4:30 p.m. ET CORALVILLE, Iowa , May 01, 2017 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a clinical-stage specialty pharmaceutical company focused on the discovery and development of proprietary
03/27/17
Summary ToggleKemPharm to Present at the 2nd Annual Neuroscience Biopartnering and Investment Forum CORALVILLE, Iowa , March 27, 2017 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a clinical-stage specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, announced today that Andrew Barrett , Ph.D., Senior Director, Scientific Affairs, will present at
03/16/17
Summary ToggleKemPharm Presents Clinical Data for Opioid Prodrug Candidates at American Academy of Pain Medicine’s Annual Meeting Poster Presentations Highlight Oral Equivalency and Intranasal Abuse Deterrence Technology CORALVILLE, Iowa , March 16, 2017 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a clinical-stage specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs,
03/09/17
Summary ToggleKemPharm, Inc. Reports Fourth Quarter and Year End 2016 Results Conference Call and Live Audio Webcast with Slide Presentation Scheduled for Today at 4:30 p.m. ET Recent Clinical Development & Regulatory Highlights : Reported Positive Data from Phase 1 Proof-of-Concept Clinical Trial of KP415 Received Clearance from FDA to Initiate Clinical Program for
02/28/17
Summary ToggleKemPharm, Inc. to Report Fourth Quarter and Year End 2016 Results Conference Call and Live Audio Webcast with Slide Presentation Scheduled for  March 9th, 2017 , 4:30 p.m. ET CORALVILLE, Iowa , Feb. 28, 2017 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a clinical-stage specialty pharmaceutical company focused on the discovery and development of proprietary
02/23/17
Summary ToggleKemPharm Announces Additional Patent Protection for Prodrug Portfolio US Patent and Trademark Office decision extends additional patent protection to KP201 and the KP511 compound family CORALVILLE, Iowa , Feb. 23, 2017 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a clinical-stage specialty pharmaceutical company focused on the discovery and development of
02/07/17
Summary ToggleKemPharm to Present at Upcoming Investor Conferences Management Presentations to Focus on Depth of Product Pipeline CORALVILLE, Iowa , Feb. 07, 2017 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a clinical-stage specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, announced today that President and
01/09/17
Summary ToggleKemPharm Reports Positive Data from Phase 1 Intranasal Pharmacokinetic Study of KP511, An Investigational Prodrug of Hydromorphone for the Treatment of Pain Statistically significant pharmacokinetic and pharmacodynamic differences of abuse potential were observed in the KP511.A01 Study CORALVILLE, Iowa , Jan. 09, 2017 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a clinical-stage specialty pharmaceutical company focused on the discovery and
01/04/17
Summary ToggleKemPharm to Present at Biotech Showcase 2017 CORALVILLE, Iowa , Jan. 04, 2017 (GLOBE NEWSWIRE) -- KemPharm, Inc. (Nasdaq:KMPH), a clinical-stage specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, announced today that its President and Chief Executive Officer, Travis Mickle , Ph.D., will present
12/20/16
Summary ToggleKemPharm Granted "Fast Track" Designation for KP201/IR KP201/IR could be the first single entity (APAP-free), IR hydrocodone product for pain analgesia with abuse-deterrent properties CORALVILLE, Iowa , Dec. 20, 2016 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a clinical-stage specialty pharmaceutical company focused on the discovery and
12/14/16
Summary ToggleKemPharm’s KP415, An Investigational Prodrug of D-Methylphenidate, Completes Phase 1 Proof-of-Concept Trial for the Treatment of ADHD   Both Early and Extended Release of the Methylphenidate Prodrug was observed in the KP415.101 Study Conference Call and Live Audio Webcast with Dr. Scott Kollins Scheduled for Today at 4:30 p.m., ET CORALVILLE, Iowa , Dec. 14, 2016 (GLOBE NEWSWIRE) -- KemPharm, Inc.
11/29/16
Summary ToggleKemPharm Receives Clearance from FDA to Initiate Clinical Program for KP201/IR, a Single-Entity Benzhydrocodone HCl Immediate Release Abuse-Deterrent Prodrug for the Treatment of Acute Pain KP201/IR could be the first single entity (APAP-free), IR hydrocodone product for pain analgesia with abuse-deterrent properties CORALVILLE, Iowa , Nov. 29, 2016 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a clinical-stage specialty pharmaceutical company focused on the discovery and
11/09/16
Summary ToggleKemPharm, Inc. Reports Third Quarter 2016 Results Conference Call and Live Audio Webcast with Slide Presentation Scheduled for Today at 5:00 p.m., ET Recent Clinical Development & Regulatory Highlights : Prioritized KP415 and KP201/IR as co-lead product candidates Received clearance from the U.S.
11/03/16
Summary ToggleKemPharm Appeals FDA Complete Response Letter on Apadaz™ by Initiating a Formal Dispute Resolution Process CORALVILLE, Iowa , Nov. 03, 2016 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a clinical-stage specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today announced it has appealed the Food and Drug Administration's ( FDA ) Complete Response Letter
11/01/16
Summary ToggleKemPharm, Inc. to Report Third Quarter 2016 Results Conference Call and Live Audio Webcast Scheduled for November 9th, 2016 , 5:00 p.m. ET CORALVILLE, Iowa , Nov. 01, 2016 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a clinical-stage specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, today
10/25/16
Summary ToggleKemPharm Files IND for KP201/IR, a Single-Entity Benzhydrocodone HCl Immediate Release Abuse-Deterrent Prodrug for the Treatment of Acute Pain KP201/IR could be the first single entity (APAP-free), IR hydrocodone product for pain analgesia with abuse-deterrent properties CORALVILLE, Iowa , Oct. 25, 2016 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a clinical-stage specialty pharmaceutical company focused on the discovery and